Abstract
AIMS: To estimate body mass index (BMI) category changes after treatment with tirzepatide as well as potential associations between shifting BMI category and selected cardiometabolic measures and weight-related patient-reported outcomes (PROs) in type 2 diabetes. MATERIALS AND METHODS: This post-hoc analysis analysed data from the SURPASS-1 to -5 trials for weekly tirzepatide (pooled doses) in adults with type 2 diabetes. Changes in BMI category from baseline to Week 40 or 52 (primary endpoint) were assessed and grouped into 'improved' (shift to ≥1 lower category) and 'not improved' (which included 'not improved: stable' [no change in category] or 'not improved: worsened' [shift to ≥1 higher category]). BMI categories were <25 kg/m(2), 25 to <30 kg/m(2), 30 to <35 kg/m(2), 35 to <40 kg/m(2), and ≥40 kg/m(2). Associations of changes in selected cardiometabolic parameters and weight-related PROs by BMI shift category were also determined. RESULTS: Overall, 58.9% of 3559 participants treated with tirzepatide shifted to an 'improved' BMI category, and 41.1% were in the 'not improved' BMI category. Participants with an 'improved' versus 'not improved' BMI category had numerically larger mean improvements from baseline in the majority of the selected cardiometabolic parameters at endpoint in all five SURPASS trials. Improvements in weight-related PROs were numerically largest for participants whose BMI category 'improved'. CONCLUSIONS: After tirzepatide treatment, approximately 60% of adults with type 2 diabetes shifted to a lower 'improved' BMI category. This shift was generally associated with numerical improvements in selected cardiometabolic measures and weight-related PROs that may reduce cardiometabolic risk.